Related Experiment Video

Updated: Mar 13, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.4K

Stratification, Hypothesis Testing, and Clinical Trial Simulation in Pediatric Drug Development

Ann W McMahon1, Kevin Watt2, Jian Wang3

  • 1Office of Pediatric Therapeutics, Office of the Commissioner, Food and Drug Administration, Silver Spring, MD, USA.

Therapeutic Innovation & Regulatory Science
|October 25, 2016
PubMed

Insights

Age stratification in pediatric drug trials is crucial. Failing to account for age-specific differences in Kawasaki disease (KD) can lead to incorrect drug approval decisions.

Area of Science:

  • Pharmacology
  • Clinical Trials
  • Pediatric Medicine

Background:

  • Pediatric drug development faces challenges like small sample sizes and unvalidated endpoints.
  • Limited studies hinder the understanding of drug efficacy in diverse pediatric populations.

Purpose of the Study:

  • To evaluate age stratification for assessing pharmacologic intervention response in pediatrics.
  • To utilize clinical trial simulation (CTS) for designing future pediatric trials based on stratified data.

Main Methods:

  • Literature data for Kawasaki disease (KD) was used for modeling.
  • Age-stratified clinical trial simulations (CTS) were performed for a hypothetical drug.

Main Results:

  • Age-specific differences significantly impact pediatric trial outcomes.
  • CTS demonstrated that inclusion criteria and inflammatory indices affect trial success.
  • Altered pharmacokinetics/pharmacodynamics in different age groups can influence drug exposure and response.

Conclusions:

  • Age stratification is essential for accurate assessment of pediatric drug efficacy.
  • Excluding age stratification in pediatric disease studies, like KD, risks inappropriate drug approval decisions.
Abstract

Keywords:
Kawasaki diseaseage groupsmodelingpharmacokinetics pharmacodynamics

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K
In Silico Clinical Trials for Cardiovascular Disease09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.3K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
11.0K
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.3K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
308
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
414
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
349